Since 1985, Atto Bioscience (formerly Atto Instruments) has provided innovative solutions to pharmaceutical, academic, and research groups in cellular biology. Combining the proven expertise of its top scientists with its unique, flexible, and easily-integrated technology, Atto redefines cellular research and drug discovery with customized andinnovative approaches that enhance any research process.Atto’s key competitive advantage is the ability to integrate biology, imaging instrumentation, engineering, and manufacturing and to deliver to the life science, pharmaceutical and toxicology community a comprehensive offering of assays, instrumentation and services. Their in-house design and development of technology affords us a better understanding of application areas allowing us to adapt to the demands of their customers, and to quickly engineer and develop state-of-the-art imaging solutions to meet those demands.In the summer of 2001, Atto reorganized to expand into the drug discovery market place. As part of the reorganization Atto expanded their management and business teams and has doubled the size of the company over the last year.Atto also strengthened its scientific teams by bringing in some of the lead scientists in cell and molecular biology also from Life Technologies.These new personnel additions along with new venture money have allowed Atto to aggressively move into the high-throughput cell imaging marketplace. From secondary screening techniques to pre-clinical research, Atto technologies and expertise creates improved strategies for reducing time and increasing downstream success.

Biotechnology

ATTO Technology, Inc.

Tim Klein

Michael Birkman

Michelle Seifert

Kurt Beyer

Jack Snyder

Dan O'Brocta

Peter Donnelly

Jeff Marks

James Masiello

David Snell

ATTO Technology, Inc.

Org chart

Similar companies